Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain.
Wang, Eric J, Dolomisiewicz, Edward, Karri, Jay et al. · The Korean journal of pain · 2023 · DOI
Quick Summary
This review examined whether antibiotics and similar antimicrobial medications might help reduce chronic pain in certain conditions, including ME/CFS. The researchers found that some of these medications appear to reduce pain in conditions where dysbiosis (imbalanced gut bacteria) or hidden infections may play a role. However, the evidence is still observational rather than definitively proving cause-and-effect relationships.
Why It Matters
ME/CFS is explicitly discussed as a condition where antimicrobial therapies may have analgesic potential, particularly if dysbiosis or subclinical infection contribute to pain. Understanding whether antimicrobials could address pain in ME/CFS—a debilitating symptom for many patients—could inform treatment decisions. This review provides a framework for identifying which antimicrobials warrant further investigation in ME/CFS research.
Observed Findings
Antimicrobials show analgesic effects in conditions associated with dysbiosis or subclinical infection, including ME/CFS.
Which specific antimicrobials and patient phenotypes would benefit most from treatment in ME/CFS?
What This Study Does Not Prove
This review does not establish that antimicrobials definitively cause pain reduction or that infection/dysbiosis is the primary mechanism of pain in ME/CFS. Most included studies are observational, preventing causal inference. The authors explicitly state that antimicrobials cannot become primary analgesic drugs and should only be considered when clinical justification for antimicrobial use already exists.